Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT Haplo17 RIC study of reduced-dose and shortened-duration immunosuppression after haploidentical transplantation
jRCTs011180014Phase 2Completed
- Sponsor
- ICMR-Regional Medical Research Centre
- Start
- Jun 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, tacrolimus, mycophenolate mofetil, fludarabine and busulfan in hematopoietic malignancies, sponsored by ICMR-Regional Medical Research Centre. Primary endpoint: Non-relapse mortality at 180 days. Started Jun 2017; status: completed.
02
Drugs
cyclophosphamidetacrolimusmycophenolate mofetilfludarabinebusulfan
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs011180014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180014.